Moving forward on the pathway of cell-based therapies in ischemic heart disease and heart failure - time for new recommendations?

ABSTRACT: Although substantial advances have been made in treating ischemic heart disease and subsequent heart failure, the overall morbidity and mortality from these conditions remain high. Stem cell-based therapy has emerged as a promising approach for prompting cardiac rejuvenation. Various cell types have been tested in the clinical arena, proving consistent safety results. As for efficiency outcomes, contradictory findings have been reported, partly due to inconsistency in study protocols but also due to poor survival, engraftment and differentiation of transplanted cells in the hostile milieu of the ischemic host tissue. Studies have varied in terms of route of delivery, type and dose of implanted stem cells, patient selection and randomization, and assessment of therapeutic effect. Founded on

SUBMITTER: Micheu MM 

PROVIDER: S-EPMC6716081 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature